RadNet Inc. (NASDAQ:RDNT) was the target of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 1,160,000 shares, a decrease of 18.3% from the January 15th total of 1,420,000 shares. Based on an average trading volume of 513,300 shares, the short-interest ratio is presently 2.3 days. Currently, 2.8% of the shares of the company are short sold.

In related news, Director John V. Crues sold 20,000 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $18.01, for a total value of $360,200.00. Following the transaction, the director now directly owns 414,097 shares in the company, valued at $7,457,886.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Norman R. Hames sold 10,327 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $18.92, for a total transaction of $195,386.84. Following the completion of the transaction, the insider now owns 532,691 shares in the company, valued at $10,078,513.72. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Samalin Investment Counsel LLC acquired a new stake in RadNet during the fourth quarter worth about $110,000. LS Investment Advisors LLC acquired a new stake in RadNet during the fourth quarter worth about $129,000. SG Americas Securities LLC acquired a new stake in RadNet during the fourth quarter worth about $152,000. Mercer Global Advisors Inc. ADV grew its stake in RadNet by 17.6% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 12,440 shares of the medical research company’s stock worth $253,000 after buying an additional 1,860 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan acquired a new stake in RadNet during the fourth quarter worth about $256,000. Hedge funds and other institutional investors own 63.43% of the company’s stock.

Shares of RDNT stock traded up $0.17 on Friday, hitting $22.87. The company’s stock had a trading volume of 169,836 shares, compared to its average volume of 285,140. The company has a debt-to-equity ratio of 5.01, a quick ratio of 0.77 and a current ratio of 0.77. The stock’s 50 day moving average is $21.20 and its 200-day moving average is $17.29. RadNet has a fifty-two week low of $11.60 and a fifty-two week high of $23.35. The company has a market capitalization of $1.14 billion, a PE ratio of 34.19, a PEG ratio of 5.32 and a beta of 0.92.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.05). The firm had revenue of $292.70 million for the quarter, compared to analyst estimates of $283.39 million. RadNet had a return on equity of 16.52% and a net margin of 3.02%. The company’s quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 earnings per share. On average, research analysts forecast that RadNet will post 0.21 earnings per share for the current year.

Several research firms recently commented on RDNT. ValuEngine upgraded shares of RadNet from a “sell” rating to a “hold” rating in a research note on Thursday, February 6th. BidaskClub downgraded shares of RadNet from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 6th. Zacks Investment Research downgraded shares of RadNet from a “buy” rating to a “hold” rating in a research note on Wednesday, January 15th. Finally, Sidoti upped their price target on shares of RadNet from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. RadNet presently has a consensus rating of “Buy” and a consensus price target of $19.50.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Read More: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.